AstraZeneca PLC
[WKN: 886455 | ISIN: GB0009895292]
Aktienkurse
127,050€ 4,74%
Echtzeit-Aktienkurs AstraZeneca PLC
Bid: Ask:
Reuters Kategorien
dpa-AFX Compact / dpa-AFX PRO Kategorien
Traderfox: dpa-AFX ProFeed Kategorien
dpa-AFX ProFeed Kategorien

Tagrisso recommended for EU approval - LAURA

18 November 2024 Tagrisso recommended for approval in the EU by CHMP for patients with unresectable EGFR-mutated lung cancer  Recommendation based on LAURA Phase III…

AstraZeneca invests $3.5 billion in US

12 November 2024 AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States AstraZeneca today announces $3.5 billion of capital investment…

Dato-DXd new BLA submitted, NSQ BLA withdrawn

12 November 2024 Datopotamab deruxtecan new BLA submitted for accelerated approval in the US for patients with previously treated advanced EGFR-mutated non-small…

9M and Q3 2024 Results

AstraZeneca 12 November 2024 9M and Q3 2024 results Upgrade to full year 2024 guidance underpinned by strong underlying growth momentum Revenue and EPS…

AstraZeneca Aktie: Kursrückgang übertrieben

Toronto (www.aktiencheck.de) - AstraZeneca-Aktienanalyse von BMO Capital Markets: 1. Überblick über die Situation AstraZeneca plc (ISIN: GB0009895292, WKN: 886455, Ticker-Symbol: ZEG, London…

GOLDMAN SACHS stuft ASTRAZENECA auf Buy

NEW YORK (dpa-AFX Analyser) - Die US-Investmentbank Goldman Sachs hat die Einstufung für Astrazeneca mit einem Kursziel von 16046 Pence…

UBS stuft ASTRAZENECA auf Sell

ZÜRICH (dpa-AFX Analyser) - Die schweizerische Großbank UBS hat die Einstufung für Astrazeneca auf "Sell" mit einem Kursziel von 11.300…

Total Voting Rights

1 November 2024 15:00 GMT Transparency Directive Voting rights and capital The following notification is made in accordance with the UK Financial Conduct…

AZN China President under investigation

This announcement contains inside information 30 October 2024 AstraZeneca China President currently under investigation Leon Wang, Executive Vice President International and AstraZeneca China…